Broad-spectrum antiviral drugs are under development to treat emerging viral diseases such as Ebola and dengue for which no specific, licensed treatments exist

Read Full Paperexternally

AIに質問

Bookmark

View Full Paper

AIに質問

Bookmark

View Full Paper

Cite This Study

Bekerman et al. (Thu,) studied this question.

synapsesocial.com/papers/69f5aa0fb29b8f3d19794ec4 https://doi.org/https://doi.org/10.1126/science.aaa3778

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Favipiravir (T-705), a novel viral RNA polymerase inhibitor2013 · 1,069 citations
2Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX44302014 · 607 citations
3Identification and Targeting of an Interaction between a Tyrosine Motif within Hepatitis C Virus Core Protein and AP2M1 Essential for Viral Assembly2012 · 158 citations
4Clinical uses of interferons2007 · 96 citations
5Nitazoxanide: A first-in-class broad-spectrum antiviral agent2014 · 569 citations

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Favipiravir (T-705), a novel viral RNA polymerase inhibitor2013 · 1,069 citations
2Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX44302014 · 607 citations
3Identification and Targeting of an Interaction between a Tyrosine Motif within Hepatitis C Virus Core Protein and AP2M1 Essential for Viral Assembly2012 · 158 citations
4Clinical uses of interferons2007 · 96 citations
5Nitazoxanide: A first-in-class broad-spectrum antiviral agent2014 · 569 citations